USFDA issues 2 observations for Strides Pharma Science subsidiary Chennai facility

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-04-06 11:15 GMT   |   Update On 2024-04-06 11:15 GMT
Advertisement

Bengaluru: Strides Pharma Science Limited has informed in a BSE filing that the United States Food and Drug Administration (USFDA) has issued two observations after a routine current Good Manufacturing Practices (cGMP) inspection at the Formulations Facility of Strides Alathur Private Limited, a wholly-owned subsidiary of the Company, at Alathur, Chennai.

USFDA inspected the facility during the week of April 1, 2024 to April 5, 2024.

Advertisement
"Company will respond to these observations comprehensively to FDA within the stipulated time," Strides added.

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor‐ funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries.

Read also: Strides Pharma Science Singapore arm gets USFDA okay for fibromyalgia drug Pregabalin


Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News